Monitor for future 424B filings or company announcements, which would signal an actual drawdown from this ATM facility and provide details on pricing and volume. The mere authorization of the facility is not a trading event.
Price Chart
Executive Summary
Lipocine Inc. (LPCN) filed a prospectus supplement to its existing sales agreement with A.G.P./Alliance Global Partners, authorizing the potential sale of up to $50 million in common stock through an at-the-market (ATM) equity offering. This is a routine capital-raising mechanism and does not indicate an immediate sale of shares.
Key Facts
- Lipocine Inc. (LPCN) filed a prospectus supplement on February 26, 2026.
- The filing relates to an existing sales agreement with A.G.P./Alliance Global Partners, originally entered into on April 26, 2024.
- The prospectus supplement authorizes the potential sale of up to $50,000,000 of common stock under the ATM program.
- The filing includes a legal opinion on the validity of the shares to be sold.
Financial Impact
Up to $50,000,000 in potential future dilution, subject to market conditions and company discretion.
Risk Factors
- Future sales under this program will be dilutive to existing shareholders.
- Sales are likely to occur when the stock price is rising, which could put downward pressure on the share price.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-008852 |
| Exhibit: ex5-1.htm | 0001493152-26-008852 |
| Document: 0001493152-26-008852-index-headers.html | 0001493152-26-008852 |
| Document: 0001493152-26-008852-index.html | 0001493152-26-008852 |
| Document: 0001493152-26-008852.txt | 0001493152-26-008852 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | 8-K | $1.62 | awaiting T+60 | — | $1.47 (−9.26%) |
Oct 7, 2026 20d ago | 8-K | $2.20 | awaiting T+60 | — | $1.47 (−33.18%) |
Sep 16, 2026 5w ago | 8-K | $2.22 | awaiting T+60 | — | $1.47 (−33.78%) |
Sep 14, 2026 6w ago | 8-K | $2.22 | awaiting T+60 | — | $1.47 (−33.78%) |
Sep 11, 2026 6w ago | 8-K | $2.27 | awaiting T+60 | — | $1.47 (−35.24%) |
Sep 10, 2026 6w ago | 8-K | $2.25 | awaiting T+60 | — | $1.47 (−34.67%) |
Aug 4, 2026 12w ago | Press Release | $2.13 | awaiting T+60 | — | $1.47 (−30.99%) |
Aug 3, 2026 12w ago | 8-K | $2.11 | awaiting T+60 | — | $1.47 (−30.33%) |
Jun 4, 2026 20w ago | 8-K | $2.21 $2.17 | ▼ −1.81% | ▼ −3.69% | $1.47 (−33.48%) |
May 26, 2026 21w ago | 8-K | $2.28 $2.09 | ▼ −8.33% | ▼ −10.21% | $1.47 (−35.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers